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Objectives This study sought to examine the efficacy of ranolazine versus placebo on weekly angina frequency and sublin-
gual nitroglycerin use in subjects with type 2 diabetes mellitus, coronary artery disease (CAD), and chronic stable
angina who remain symptomatic despite treatment with up to 2 antianginal agents.
Background Patients with diabetes have more extensive CAD than those without diabetes, and a high burden of angina. Ra-
nolazine is not only effective in treating angina but also may improve glycemic control, thus providing several
potential benefits in this high-risk group. We conducted a randomized trial to test the antianginal benefit of rano-
lazine in patients with diabetes and stable angina.
Methods TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) was an international,
randomized, double-blind trial of ranolazine versus placebo in patients with diabetes, CAD, and stable angina
treated with 1 to 2 antianginals. After a single-blind, 4-week placebo run-in, patients were randomized to 8 weeks of
double-blind ranolazine (target dose 1000 mg bid) or placebo. Anginal episodes and nitroglycerin use were re-
corded with daily entry into a novel electronic diary. Primary outcome was the average weekly number of angi-
nal episodes over the last 6 weeks of the study.
Results A total of 949 patients were randomized across 104 centers in 14 countries. Mean age was 64 years, 61% were
men, mean diabetes duration was 7.5 years, and mean baseline HbA1c was 7.3%. Electronic diary data capture
was 98% in both groups. Weekly angina frequency was significantly lower with ranolazine versus placebo (3.8
[95% confidence interval (CI): 3.6 to 4.1] episodes vs. 4.3 [95% CI: 4.0 to 4.5] episodes, p  0.008), as was the
weekly sublingual nitroglycerin use (1.7 [95% CI: 1.6 to 1.9] doses vs. 2.1 [95% CI: 1.9 to 2.3] doses, p 
0.003). There was no difference in the incidence of serious adverse events between groups.
Conclusions Among patients with diabetes and chronic angina despite treatment with up to 2 agents, ranolazine reduced
angina and sublingual nitroglycerin use and was well tolerated. (Type 2 Diabetes Evaluation of Ranolazine in
Subjects With Chronic Stable Angina [TERISA]; NCT01425359) (J Am Coll Cardiol 2013;61:2038–45) © 2013
by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.011r
a
aDespite multiple medical and interventional technologies to
reduce myocardial ischemia, chronic angina still affects
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it is associated with worse health-related quality of life (2,3),
epeat hospitalizations, and increased healthcare costs (4),
ngina remains frequently undertreated (5,6). Patients with
ngina and concomitant type 2 diabetes mellitus (T2DM)
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May 21, 2013:2038–45 Antianginal Effect of Ranolazine in T2DMrepresent a particularly challenging group, as they often have
more diffuse and extensive coronary artery disease (CAD) as
compared with those without T2DM (7,8). Furthermore,
patients with CAD and T2DM may also have a greater
burden of angina than those without diabetes (9,10). Tar-
geted approaches to reduce the burden of angina specifically
among patients with T2DM could have a substantial impact
on quality of life.
Ranolazine, a selective inhibitor of the late sodium
current (late INa) (11), has been proven effective in treating
hronic angina both as a monotherapy (12,13) and in
ombination with other commonly prescribed antianginal
edications (14,15). Furthermore, among patients with
oorly controlled T2DM, ranolazine may lower fasting
lucose and HbA1c (10,16,17). Although post hoc analyses
f prior trials have suggested an antianginal benefit among
atients with T2DM (10,17), this hypothesis has not been
rospectively tested. Accordingly, we sought to test the
fficacy of ranolazine in reducing angina among patients
ith T2DM, CAD, and chronic angina who remain symp-
omatic despite treatment with other agents.
ethods
tudy overview. TERISA (Type 2 Diabetes Evaluation of
anolazine in Subjects With Chronic Stable Angina) was a
andomized, double-blind, placebo-controlled trial in which
ubjects with stable angina and T2DM were randomized to
wice daily placebo or ranolazine for 8 weeks (Fig. 1). The
tudy was conducted in 14 countries across Asia, Europe,
nd North America, and was approved by the national
egulatory authority in each participating country and by the
nstitutional review board or local ethics committee for each
ite. All participating subjects gave written informed con-
ent. The full study protocol and the list of participating sites
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2013, accepted February 19, 2013.nd investigators can be found in
he Online Appendix (Online
xhibit A, Online Table 1). The
rimary aim of the trial was to
xamine the efficacy of ranola-
ine versus placebo on weekly
ngina frequency in subjects with
2DM, CAD, and chronic sta-
le angina who remain symp-
omatic despite treatment with 1
r 2 antianginal agents.
atient selection. Full inclusion
nd exclusion criteria may be
ound in the Online Appendix
Online Exhibit A). Briefly, to be eligible for randomization
n TERISA, subjects had to have a documented history of
oth T2DM and CAD, and at least a 3-month history of
hronic stable angina. Subjects were further required to be
reated with 1 or 2 antianginal therapies (beta-blockers,
alcium-channel blockers, long-acting nitrates) at a stable
ose for at least 2 weeks prior to study entry. Key exclusion
riteria were New York Heart Association functional class
II to IV heart failure symptoms, acute coronary syndrome
n the prior 2 months, planned coronary revascularization
uring the study period, stroke or transient ischemic attack
ithin 6 months prior to screening, uncontrolled hyperten-
ion, clinically significant hepatic impairment, prior treat-
ent with ranolazine, and dialysis.
tudy design. Eligible subjects entered a 4-week, single-
lind placebo run-in period and were provided a novel,
andheld electronic diary (LogPad LV diary, PHT Corpo-
ation, Boston, Massachusetts) (Online Fig. 1), with
uilt-in electronic prompts for daily entry. Subjects were
nstructed to record and transmit the data to the coordinat-
ng center every evening, including the number of angina
pisodes and number of sublingual nitroglycerin (SL NTG)
oses taken since the previous evening. Subjects taking 2
ntianginal medications at screening were allowed to wash-
ut additional antianginal therapies 2 weeks prior to the
un-in period. To be randomized at the end of the run-in
eriod, subjects were required to meet the following criteria:
) 85% adherence to daily electronic diary data entry
including angina frequency and SL NTG use) with no
eek with5 days of diary use; 2) an average weekly angina
requency between 1 and 28 and at least 1 angina episode
uring each week; and 3) 80% adherence with single-
lind placebo. Subjects were then randomized in a double-
lind fashion to either ranolazine or placebo for 8 weeks
Online Fig. 2). Ranolazine (Gilead Sciences, Foster City,
alifornia) or matching placebo was initiated at 500 mg
wice daily (bid) for 1 week and, if tolerated, increased to
,000 mg bid (subjects taking verapamil or diltiazem were
aintained on 500 mg bid of ranolazine or matching
lacebo). Randomization was stratified by the following:
) average number of weekly angina episodes during trial
Abbreviations
and Acronyms
CAD  coronary artery
disease
late INa  late sodium
current
SF-36  Medical Outcomes
Short Form-36
SL NTG  sublingual
nitroglycerin
T2DM  type 2 diabetes
mellitusun-in (1 and 3 vs. 3 and 28); 2) number of concom-
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Antianginal Effect of Ranolazine in T2DM May 21, 2013:2038–45itant antianginal agents (1 vs. 2); 3) geographic region (Russia,
Ukraine, and Belarus vs. Other). The proportion of subjects
being treated with 2 concomitant antianginal medications was
capped at 50%, and the proportion of subjects with baseline
average weekly angina frequency 3 was capped at 30%.
umber and doses of concomitant antianginal medications
ere kept stable during the study per protocol.
tudy endpoints. The primary outcome was the average
umber of angina episodes per week from weeks 2 to 8 of
reatment. Pre-specified secondary endpoints included av-
rage weekly frequency of SL NTG use, number of angina-
ree days, proportion of subjects with 50% reduction in
verage weekly angina frequency, and health-related quality
f life, as assessed by the Medical Outcomes Short Form-36
SF-36) (18) and the Patient’s Global Impression of
hange scale score (19).
tatistical analysis. Full details of the statistical analysis plan
ay be found in the Online Appendix (Online Exhibit B).
ssuming an average weekly angina frequency of 2.0 epi-
odes on placebo, we estimated that a sample size of 900
ubjects, randomized in a 1:1 ratio to ranolazine and
lacebo, would provide 90% power to show a relative
eduction of 20% in weekly angina frequency with ranola-
ine as compared with placebo.
The pre-specified efficacy analyses included all random-
zed subjects who took at least 14 days of the study drug,
ompleted at least 1 diary entry, and met all major eligibility
Figure 1 Enrollment and Randomization of Patients With Type
Eligible subjects entered a 4-week, single-blind placebo run-in period. To be rando
daily electronic diary data entry with no week with 5 days of diary use; 2) an ave
each week; and 3) 80% adherence with single-blind placebo. Randomized patien
the safety analyses. The efficacy analyses included all randomized subjects who t
major eligibility criteria.riteria. The primary efficacy analysis comparing weekly 2ngina frequency was performed by fitting a generalized
inear model with negative binomial distribution, as was the
nalysis of average weekly SL NTG use. Pre-specified
ubset analyses included the following: 1) average number of
eekly angina episodes at baseline (3 vs. 3); 2) number
f concomitant antianginal agents (1 vs. 2); 3) geographic
egion (Russia, Ukraine, and Belarus vs. Other); 4) age
65 vs. 65 years); and 5) sex (male vs. female). In
ddition, a number of exploratory stratified analyses were
erformed, including history of percutaneous coronary in-
ervention (yes vs. no); history of coronary artery bypass
raft surgery (yes vs. no); and HbA1c at various thresholds.
All analyses were conducted using SAS version 9.2 (SAS
nstitute, Inc., Cary, North Carolina), and statistical signif-
cance was determined by a 2-sided p value of 0.05. A
re-specified testing sequence incorporating Hochberg ad-
ustments was used to preserve the type I error rate.
tudy oversight. The study was sponsored by Gilead
ciences (Foster City, California). Statistical analysis was
erformed by Saint Luke’s Mid America Heart Institute
ndependent of the sponsor. The decision to submit the
anuscript for publication was made by the publication
ommittee (Online Table 2).
esults
tudy population. From October 5, 2011, to July 20,
betes Mellitus and Stable Angina in the TERISA Trial
subjects were required to meet the following criteria: 1) 85% adherence to
eekly angina frequency between 1 and 28 and at least 1 angina episode during
took at least 1 dose of the study drug (ranolazine or placebo) were included in
least 14 days of the study drug, completed at least 1 diary entry, and met all2 Dia
mized,
rage w
ts who
ook at012, 1,185 patients were screened (Fig. 1). Of these, 1,142
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May 21, 2013:2038–45 Antianginal Effect of Ranolazine in T2DMpatients were considered trial-eligible, signed informed
consent, and entered into a 4-week single-blind placebo
run-in period. A total of 193 patients failed the run-in
period and were excluded prior to randomization; 949
patients were randomized (473 to ranolazine, 476 to pla-
cebo). Twenty-two patients that either never initiated or
discontinued the study drug during the first 2 weeks (11 in
the ranolazine arm, 11 in the placebo arm) were excluded
from the analysis, leaving the final analytic sample size of
927 patients (462 in the ranolazine arm, 465 in the placebo
arm). The target dose of ranolazine or matching placebo
(1,000 mg bid or 500 mg bid in the presence of diltiazem or
verapamil) was achieved in 95% of patients.
Baseline characteristics of the randomized patients are
listed in Table 1, and were well matched between groups.
The mean age was 64 8.5 years, 61% were male, and 99%
were white. Seventy percent of subjects were enrolled in
Russia, Ukraine, and Belarus, and 30% were enrolled in
other countries (enrollment by country, Online Table 3).
CAD risk factors were common, including hypertension
(96%), dyslipidemia (80%), and smoking (16%); and the
majority of patients had a previous myocardial infarction
(74%) and prior revascularization (51%). Average diabetes
Baseline Characteristics of the Patients,According to the Study GroupTable 1 B seline Cha act ristics of the Patients,According to the Study Group
Ranolazine (n  462) Placebo (n  465)
Age, yrs 63.2 8.5 64.2 8.4
Men 283 (61.3%) 286 (61.5%)
White 456 (98.7%) 462 (99.4%)
Hypertension 438 (95.0%) 445 (95.9%)
Dyslipidemia 350 (79.4%) 355 (80.3%)
Current smoking 71 (15.4%) 77 (16.6%)
Prior myocardial infarction 346 (75.4%) 336 (72.7%)
Prior angioplasty 197 (42.7%) 180 (38.8%)
Prior bypass graft surgery 84 (18.2%) 88 (18.9%)
Duration of diabetes, yrs 7.2 6.7 7.7 7.0
HbA1c, % 7.3 1.5 7.3 1.5
Antidiabetic medication 431 (93.3%) 431 (92.7%)
Insulin 81 (17.5%) 96 (20.6%)
Antianginal medications
On 1 259 (56.1%) 259 (55.7%)
On 2 203 (43.9%) 206 (44.3%)
Beta-blockers 418 (90.5%) 418 (89.9%)
Calcium-channel blockers 124 (26.8%) 143 (30.8%)
Long-acting nitrates 161 (34.8%) 151 (32.5%)
Statins 381 (82.5%) 383 (82.4%)
Antiplatelet agents 415 (89.8%) 402 (86.5%)
ACE-I/ARBs 407 (88.1%) 407 (87.5%)
Baseline heart rate
(beats/min)
69.0 8.0 70.0 9.8
Baseline systolic blood
pressure (mm Hg)
131.0 11.0 131.0 11.3
Baseline diastolic blood
pressure (mm Hg)
79.0 7.7 79.0 7.8
Values are n mean  SD or (%).
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker.duration was 7.5 6.8 years, mean HbA1c was 7.3 1.5%, cand 93% of patients were treated with glucose-lowering
medications, including 19% treated with insulin.
A total of 56% of patients were treated with 1 antianginal
agent, with the remainder receiving 2 agents at baseline.
Most patients were treated with beta-blockers (90%), with
lower rates of calcium channel blocker (29%) and long-
acting nitrate use (34%). The use of concomitant cardiovas-
cular medications was high, including statins (82%), anti-
platelet agents (88%), and angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers (88%).
Primary outcome. Compliance with electronic diary sub-
mission of patient-reported angina frequency and SL NTG
was high (98% of all patient-days during weeks 2 to 8 of
treatment had a diary entry, both in ranolazine and placebo
arms). During the 4-week run-in phase, average weekly
angina frequency was similar between the ranolazine and
placebo groups (6.6 [95% confidence interval (CI): 6.27 to
7.02] episodes vs. 6.8 [95% CI: 6.42 to 7.19] episodes, p 
.54). Though patients treated with placebo had a substan-
ial decrease in angina frequency, weekly angina frequency
as significantly lower in the ranolazine group than in the
lacebo group during weeks 2 to 8 after randomization (3.8
95% CI: 3.57 to 4.05] episodes vs. 4.3 [95% CI: 4.01 to
.52] episodes, p  0.008) (Fig. 2A, Table 2).
econdary outcomes. At baseline, there was no statistical
ifference in average weekly SL NTG use between the
anolazine and placebo groups (4.1 [3.74 to 4.60] vs. 4.5
4.05 to 4.98] doses, p  0.27). During weeks 2 to 8 after
andomization, the average weekly number of SL NTG
oses was significantly lower in the ranolazine group (Fig. 2B),
nd was significantly lower in the ranolazine group than in
he placebo group (1.7 [95% CI: 1.58 to 1.92] vs. 2.1 [95%
I: 1.92 to 2.31] doses, p  0.003) (Fig. 2B, Table 2).
During weeks 2 to 8 after randomization, the proportion
f angina-free days did not differ between the ranolazine
nd placebo groups (67% vs. 64%, p  0.068) (Table 2).
he proportion of patients achieving at least 50% reduction
n weekly angina frequency was higher in the ranolazine
han placebo group (47% vs. 42%, p  0.034), and the
ncrease from baseline to end of treatment in SF-36 Physical
omponent Summary Score was also greater in the rano-
azine than placebo group (2.9 [95% CI: 2.3 to 3.5] points
s. 1.9 [95% CI: 1.3 to 2.5] points, p  0.005). However,
hese latter 2 differences were not considered statistically
ignificant (despite p values 0.05) based on the pre-
pecified multiple testing procedure. There was no differ-
nce between the ranolazine and placebo groups in the
hange in SF-36 Mental Component Score (1.0 [95% CI:
.18 to 1.82] points vs. 1.1 [95% CI: 0.28 to 1.92] points,
 0.77) or in the Patient’s Global Impression of Change
cale score at end of treatment (4.0 [95% CI: 3.82 to 4.19]
s. 3.9 [95% CI: 3.74 to 4.10], p  0.41).
ubgroup analyses. The results of subgroup analyses are
resented in Figures 3A and 3B. The superior efficacy of
anolazine versus placebo on the primary endpoint was
onsistent in the pre-specified subgroups of baseline average
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Antianginal Effect of Ranolazine in T2DM May 21, 2013:2038–45weekly angina episodes (3 vs. 3; pinteraction  0.85),
number of concomitant antianginal medications (1 vs. 2;
pinteraction  0.89), age (65 vs. 65; pinteraction  0.97),
nd sex (pinteraction  0.46). There was a significant inter-
action in the effect of ranolazine versus placebo on the
primary endpoint by the geographic region of enrollment
(Russia, Ukraine and Belarus vs. Other; pinteraction 0.016).
aseline characteristics by enrollment region stratified by
andomized treatment assignment are presented in Online
able 4. The average number of weekly angina episodes
uring the treatment phase decreased significantly in both
reatment groups (Online Fig. 3), but was not statistically
ifferent between the ranolazine and placebo arms among
atients enrolled in Russia, Ukraine, and Belarus (4.1 [95%
I: 3.9 to 4.4] vs. 4.3 [95% CI: 4.1 to 4.6], p  0.31).
However, among patients enrolled in other countries, those
treated with ranolazine experienced a significant reduction
in average weekly angina episodes as compared with
placebo-treated patients (3.1 [95% CI: 2.8 to 3.5] vs. 4.1
[95% CI: 3.7 to 4.6], p  0.002) (Online Fig. 3).
In exploratory analyses, the greater therapeutic benefit of
ranolazine versus placebo was consistent across revascular-
ization subgroups (Fig. 3A). However, the therapeutic
superiority of ranolazine versus placebo on reducing weekly
angina frequency was more pronounced in patients with
higher baseline HbA1c, regardless of the HbA1c threshold
Figure 2 Weekly Angina Frequency and Use of SL NTG, by Stud
Average weekly angina frequency (A) and sublingual nitroglycerin (SL NTG) use (B
4-week, single-blind, placebo phase. Randomization occurred at week 4 (dashed l
ing placebo was initiated at 500 mg bid for 1 week and, if tolerated, increased to
angina frequency during weeks 2 to 8 of the treatment phase. Weekly SL NTG use
confidence intervals are plotted due to skewed distributions.used (pinteraction  0.027) (Fig. 3B).Safety. There was no difference in the incidence of serious
adverse events between groups (Table 2). Of the 20 subjects
discontinued from the study due to adverse events, 9 were in
the ranolazine group and 11 were in the placebo group. Five
subjects died during the study, 3 in the ranolazine group (2
myocardial infarctions and 1 sudden cardiac death) and 2 in
the placebo group (1 acute cardiac failure and 1 pulmonary
embolism). Nonserious adverse events of nausea, dizziness,
and constipation occurred more frequently with ranolazine
compared with placebo.
Discussion
In this trial of patients with T2DM, established CAD, and
stable angina, ranolazine was more effective than placebo in
reducing the primary outcome of average weekly angina
episodes, as well as average weekly sublingual nitroglycerin
use. These results were consistent across the subgroups of
baseline average weekly angina episodes, number of con-
comitant antianginal medications, age, and sex. The thera-
peutic benefit of ranolazine versus placebo was greater
among patients enrolled outside of Russia, Ukraine, and
Belarus, and among those with higher baseline HbA1c. In
addition, ranolazine was safe and well tolerated in this
patient population.
While patients with T2DM and CAD have more exten-
up
udy group, as recorded in the electronic diary. The run-in phase refers to the
fter which subjects entered a double-blind treatment phase. Ranolazine or match-
0 mg bid with ranolazine or matching placebo. The primary outcome was weekly
g weeks 2 to 8 was the key secondary outcome. The geometric means and 95%y Gro
) by st
ine), a
a 1,00
durinsive disease (7,8) and worse outcomes (20,21) than those
ays of
utcome
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May 21, 2013:2038–45 Antianginal Effect of Ranolazine in T2DMwithout DM, the data on whether they experience more
angina are conflicting. Several older studies suggested that
patients with DM have less angina than their non-DM
counterparts due to an increased likelihood of “silent”
ischemia related to diabetic autonomic neuropathy (22–24).
However, both a recent observational study and a multina-
tional clinical trial demonstrated that patients with DM
experienced a higher burden of angina compared with
patients without DM after an acute coronary syndrome
(9,10). Given the high prevalence of angina in patients with
DM, as well as its relationship with worse health-related
quality of life (2,3), greater risk of repeat hospitalizations,
and increased healthcare costs (4), effective therapeutic
strategies for angina management in this patient group are
clinically important.
To our knowledge, the TERISA trial is the first random-
ized clinical trial to study antianginal medical therapy
(ranolazine or otherwise) specifically in patients with
T2DM—a high-risk and therapeutically challenging group.
A post hoc analysis of the CARISA (Combination Assess-
ment of Ranolazine in Stable Angina) randomized trial that
evaluated ranolazine versus placebo among patients with
stable angina showed that ranolazine decreased angina
Clinical OutcomesTable 2 Clinical Outcomes
Efficacy endpoints*
Primary endpoint
Angina frequency, baseline, n/week
Angina frequency, on treatment, n/week
Secondary endpoints
SL NTG use, baseline, n/week
SL NTG use, on treatment, n/week
Percentage of angina-free days, %
Subjects with 50% reduction in angina episodes, %
SF-36 mental component score, change from baseline
SF-36 physical component score, change from baselin
PGIC scale score
Diary compliance, %
Safety endpoints*
Serious adverse events
Serious adverse event
Death
Nonfatal myocardial infarction
Stroke/transient ischemic attack
Unstable angina or coronary revascularization
Notable nonserious adverse events
Dizziness
Nausea
Headache
Constipation
Hypoglycemia
Any adverse event
Values are least-squares mean (95% confidence interval), n (%), or me
use are presented in Online Table 5). *Analytic sample for the safety da
sample for the efficacy dataset includes patients who completed 14 d
PGIC  Patient’s Global Impression of Change; SF-36  Medical Ofrequency to a similar degree in patients with and withoutT2DM (17). Moreover, a subgroup analysis of the
MERLINTIMI 36 (Metabolic Efficiency With Ranola-
zine for Less Ischemia in Non-ST Elevation Acute Coro-
nary SyndromesThrombolysis In Myocardial Infarction
36) study of subjects following acute coronary syndromes
suggested a trend toward greater therapeutic benefit of
ranolazine versus placebo in reducing recurrent ischemia
among patients with T2DM than those without T2DM
(10). Although these observational analyses suggested an
antianginal benefit of ranolazine in patients with T2DM,
this hypothesis has not been prospectively tested until now.
By specifically focusing on patients with T2DM in a
prospective, randomized clinical trial, the TERISA trial
establishes, for the first time, the therapeutic effectiveness of
ranolazine in this patient population.
The subgroup analyses of the TERISA trial produced
intriguing findings, particularly the greater efficacy of rano-
lazine versus placebo among patients with higher HbA1c.
The mechanisms underlying this finding remain to be
determined. There is, however, evidence that cardiomyo-
cytes exposed ex vivo to high glucose, or isolated from hearts
of diabetic animals have up-regulated phosphorylated
CaMKII (25), a kinase known to phosphorylate the cardiac
Ranolazine Placebo p Value
n  462 n  465
6.6 (6.3–7.0) 6.8 (6.4–7.2) 0.54
3.8 (3.6–4.1) 4.3 (4.0–4.5) 0.008
4.1 (3.7–4.6) 4.5 (4.1–5.0) 0.27
1.7 (1.6–1.9) 2.1 (1.9–2.3) 0.003
67 (65–70) 64 (61–67) 0.068
47 (43–51) 42 (38–46) 0.034
1.0 (0.2–1.8) 1.1 (0.3–1.9) 0.77
2.9 (2.3–3.5) 1.9 (1.3–2.5) 0.005
4.0 (3.8–4.2) 3.9 (3.7–4.1) 0.41
98 (95–98) 98 (95–98) 0.46
n  470 n  474
16 (3.4) 20 (4.2) 0.51
3 (0.6) 2 (0.4) 0.69
1 (0.2) 3 (0.6) 0.62
1 (0.2) 4 (0.8) 0.37
6 (1.3) 7 (1.5) 0.79
17 (3.6) 6 (1.3) 0.019
17 (3.6) 2 (0.4) 0.001
7 (1.5) 9 (1.9) 0.63
8 (1.7) 2 (0.4) 0.063
3 (0.6) 0 (0.0) 0.12
126 (26.8) 105 (22.2) 0.096
terquartile range) (arithmetic means for angina frequency and SL NTG
cludes patients who took any dose of the study drug whereas analytic
the study drug.
s Short Form-36; SL NTG  sublingual nitroglycerin.e
dian (in
taset insodium channel resulting in an increased late INa (26),
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calcium (27). Ranolazine, an inhibitor of late INa (11),
would then be expected to have a greater therapeutic effect
in patients with poor glycemic control. Alternative explana-
tions for this observation may also exist. Beyond its anti-
anginal benefit, ranolazine may also lower HbA1c, partic-
ularly among patients with suboptimal glucose control
(16,17). Hyperglycemia may worsen myocardial perfusion
through microvascular and endothelial dysfunction, en-
hanced platelet aggregation and prothrombotic state, and
increased oxidative stress—detrimental effects that may be
reduced with better glucose control (28). Ranolazine’s an-
tianginal effect mediated through inhibition of late INa may,
therefore, be potentiated by its glucose-lowering properties
through some of these mechanisms. However, because
glucose-lowering per se has never been shown to improve
angina, this mechanism is a less plausible one. Regardless of
the underlying physiology, these findings, if confirmed in
future clinical trials, would suggest that T2DM patients
Figure 3 Subgroup Analyses of the Primary Endpoint
of Weekly Angina Frequency
Incidence density ratio (*) (or the relative difference in the incidence rates) of
weekly angina frequency, according to the generalized linear model with nega-
tive binomial distribution, within pre-specified stratifications and categorical
subgroups (A). B shows the exploratory analysis of subgroups of HbA1c by var-
ious thresholds. CABG  coronary artery bypass graft surgery; PCI  percuta-
neous coronary intervention.with angina and suboptimal glucose control may receivegreater benefit from ranolazine therapy—both in terms of
its antianginal and glucose-lowering effects.
We also observed a difference in the therapeutic effec-
tiveness of ranolazine among patients enrolled in Russia,
Ukraine, and Belarus versus other countries. Preliminary
analyses have determined that this observation was driven
primarily by several sites located in Russia and was not
explained by differences in baseline characteristics between
geographic regions. The underlying reasons behind this
finding remain uncertain and will be investigated in future
detailed analyses.
The TERISA study has several strengths. The design of
the study, including the single-blind placebo run-in period,
ensured high angina frequency at baseline and compliance
with the study medication and self-reporting of outcomes
among the study patients. It also allowed appropriate
accounting for the marked placebo effect, which is of critical
importance in clinical trials of antianginal agents. Prior
antianginal trials often compared on-treatment angina fre-
quency to a baseline value without a parallel placebo group
(29–31). The primary endpoint of the TERISA trial
(patient-reported angina frequency) was both patient-
centered and clinically meaningful. Other studies, even
when showing a reduction in intermediate measures of
angina (e.g., time to limiting angina on exercise testing),
failed to demonstrate a reduction in angina frequency
(32,33). Additionally, we used a novel electronic diary
instrument (Online Fig. 2) to record patient-reported an-
gina and SL NTG use, with outstanding compliance.
Studies using traditional paper diaries are often limited by
inappropriate input of multiple entries in a single sitting
(so-called “hoarding”) and low subject compliance (as low as
11% in 1 study) (34). Our successful use of the electronic
diary should inform the design of future clinical studies that
evaluate patient-reported outcomes. Finally, the use of
concomitant medical therapy for CAD, such as antiplatelet
agents, antihypertensive medications, and statins, was high
in both treatment groups.
Study limitations. The results of this study should be
interpreted in the context of several potential limitations.
Most of the subjects were enrolled in European centers,
thereby limiting inclusion of a racially diverse study popu-
lation. More data are needed on the effect of ranolazine
among blacks, Hispanics, and Asians. In addition, several of
the subgroup analyses were not pre-specified and should be
regarded as exploratory and hypothesis-generating. Specif-
ically, while the findings of greater ranolazine efficacy in
patients with higher HbA1c were adjusted for several key
factors (including geographic region), a possibility of resid-
ual confounding cannot be definitively ruled out. Finally, the
relatively short duration of treatment in the TERISA trial
limits our ability to know the durability of the observed
antianginal effect of ranolazine; however, prior studies have
demonstrated this effect to persist for at least 12 months (35).
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May 21, 2013:2038–45 Antianginal Effect of Ranolazine in T2DMConclusions
Among patients with T2DM, CAD, and persistent chronic
angina, despite treatment with up to 2 antianginal agents,
ranolazine significantly reduced angina frequency and SL
NTG use and was safe and well tolerated.
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APPENDIX
For Exhibit A and B and supplemental tables and figures,
please see the online version of this article.
